Intra-Cellular Therapies Inc (MEX:ITCI)
MXN 1529.77 0 (0%) Market Cap: 183.55 Bil Enterprise Value: 163.69 Bil PE Ratio: 0 PB Ratio: 8.01 GF Score: 38/100

Intra-Cellular Therapies Inc to Discuss Positive Topline Results from Study 402 - Conference Call Transcript

Sep 09, 2020 / 12:00PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies conference call announcing the top line results from Study 402. (Operator Instructions) As a reminder, today's conference call is being recorded. I would like to turn the conference over to your host, Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.

Juan Fernando Sanchez
Intra-Cellular Therapies, Inc. - VP of Corporate Communications & IR

Thank you, operator. Good morning and thank you for joining us on today's conference call announcing the positive top line results from Study 402, our study evaluating lumateperone as an adjunctive therapy in patients with bipolar depression.

Our press release announcing the results crossed the wire a short time ago and is available on our website. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer; Dr. Suresh Durgam, Senior Vice President of Late-Stage Clinical Development and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot